Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017211246) SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/211246 International Application No.: PCT/CN2017/087137
Publication Date: 14.12.2017 International Filing Date: 05.06.2017
IPC:
C07D 487/04 (2006.01) ,A61K 31/55 (2006.01) ,A61P 37/08 (2006.01) ,A61P 27/14 (2006.01) ,A61P 27/02 (2006.01) ,A61P 11/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
08
Antiallergic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
14
Decongestants or antiallergics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
02
Nasal agents, e.g. decongestants
Applicants:
深圳市塔吉瑞生物医药有限公司 SHENZHEN TARGETRX, INC. [CN/CN]; 中国广东省深圳 南山区科苑路15号科兴科学园A1栋301 Room 301, Building A1, Kexing Science Park No.15 of Keyuan Road, Nanshan District Shenzhen, Guangdong 5180057, CN
Inventors:
王义汉 WANG, Yihan; CN
邢青峰 XING, Qingfeng; CN
Priority Data:
201610397242.807.06.2016CN
Title (EN) SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
(FR) COMPOSÉ CYCLIQUE D'IMIDAZOLE CONDENSÉ SUBSTITUÉ ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE
(ZH) 一种取代的稠合咪唑环化合物及其药物组合物
Abstract:
(EN) The present invention relates to a substituted fused imidazole cyclic compound and a composition containing said compound and application thereof. Specifically disclosed is the fused imidazole cyclic compound represented by formula (I), or a pharmaceutical composition of its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvate. The compound of the present invention may be used as a histamine H1-receptor antagonist and mast-cell stabilizer, and is capable of inhibiting mast-cell release of histamine and preventing histamine function, thereby reducing allergic reaction.
(FR) La présente invention concerne un composé cyclique d'imidazole condensé substitué et une composition comportant ledit composé et une application correspondante. L'invention porte particulièrement sur le composé cyclique d'imidazole condensé représenté par la formule (I), ou sur une composition pharmaceutique de sa forme cristalline, d'un sel de qualité pharmaceutique, d'un promédicament, d'un stéréoisomère, d'un hydrate ou d'un solvate. Le composé de la présente invention peut être utilisé comme antagoniste du récepteur de l'histamine H1 et comme stabilisateur des mastocytes, et est apte à inhiber la libération de l'histamine par les mastocytes et à prévenir la fonction de l'histamine, ce qui permet de réduire la réaction allergique.
(ZH) 本发明涉及了一种取代的稠合咪唑环化合物及包含该化合物的组合物及其应用。具体地,该发明公开了式(I)所示的稠合咪唑环化合物,或其晶型、药学上可接受的盐、前药、立体异构体、水合物或溶剂合物的药物组合物。本发明所述化合物可作为组胺H1-受体拮抗剂和肥大细胞稳定剂,能抑制肥大细胞释放组胺并阻止组胺作用,从而减轻过敏反应。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)